<DOC>
	<DOCNO>NCT02728778</DOCNO>
	<brief_summary>The main objective trial test whether single application botulinum toxin A glabellar region lead emotional stabilization borderline personality disorder paralysis facial muscles/attenuation negative emotion .</brief_summary>
	<brief_title>Botulinum Toxin A Emotional Stabilization Borderline Personality Disorder ( BPD )</brief_title>
	<detailed_description>Afferent feedback facial muscle believe enhance emotional state ( facial feedback theory ) . The facial expression negative emotion involve facial muscle glabellar region . It show paralysis facial muscle forehead use botulinum toxin A lead improvement depressive symptom . It believe limited ability express emotion alleviate depressive symptom . As Borderline personality disorder characterize negative emotion express via facial muscle forehead , hypothesize BPD patient could profit botulinum toxin treatment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1. female 2 . 1840 year 3. diagnose BPD accord ICD10 ( F60.31 ) SKID II 4. stable treatment 5. mastery German language 6. effective contraception 7. willingness acceptance treatment either botulinum toxin A acupuncture 1 . Comorbid disorder ICD10 group F0 , F1 ( exception F1x.1 ) , F2 , F3 ( exception 32.0 F33.0 ) , F7 disorder essentially define clinical picture section F4 , F5 , F6 . 2 . Contraindication treatment Botulinumtoxin A accord IMP 's SmPC ( e.g . myasthenia gravis , Lambert Eatonsyndrome impairment neuromuscular function )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>